Remimazolam "Byfavo"
At Advanced Sedation we are proud to let our clients know we now offer a sedation service for adult patients who are concerned about the duration of effect of most sedatives.
We would like to introduce Byfavo - the brand name for remimazolam.
In June 2021 Paion’s ‘ultra-short-acting’ benzodiazepine, Byfavo, received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for use in procedural sedation.
It is licensed in the UK to be used in adult patients only. They should however have an appropriate escort accompany them home.
Dr Rudi has been using Byfavo since May 2022 with great success. Patients have been very impressed with the fast onset and fast clearance of the drug.
Remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and unlike midazolam it's not metabolized by cytochrome-dependent hepatic pathways.
However, like midazolam, remimazolam can be reversed with flumazenil to rapidly terminate sedation or anesthesia if necessary.
Research data demonstrate that remimazolam has a rapid onset and offset of action combined with a favorable cardio-respiratory safety profile.
Dr Rudi has since involved independent researchers to accumulate useful data illustrating the success of this drug for use in dental sedation which was published in an international journal. Here is the link to the paper : https://pubmed.ncbi.nlm.nih.gov/38068360/